KineMed and Camino Partner to Acquire Drug Candidates | GenomeWeb

NEW YORK (GenomeWeb) – KineMed and Camino Partnership today announced that they are partnering in an effort to acquire new drugs and targeted drug candidates for potential licensing opportunites.

According to the partners, KineMed plans to apply its proteomics technology in rapid proof-of-concept studies on up to six compounds over a three-year period and then out-license appropriate candidate drugs to pharmaceutical companies.

Initially, the effort will focus on drugs for oncology, neurodegenerative disorders, muscle wasting, and fibrosis diseases, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.